The CSL Ltd (ASX: CSL) share price is in focus after the company announced plans to launch clinical trials for its next-generation plasma manufacturing process, Horizon 2. This move aims to deliver significantly greater immunoglobulin output and efficiency from its operations.
Image source: Getty Images
What did CSL report?
- CSL will commence clinical trials to evaluate its Horizon 2 immunoglobulin manufacturing process.
- Horizon 2 is designed to increase yields from the same amount of plasma.
- Clinical activities are expected to start mid-2027 at the Broadmeadows facility.
- Regulatory engagements with FDA and EMA are underway to support approval.
- Trials will run alongside the Kankakee, Illinois site expansion.
What else do investors need to know?
CSL's investment in advanced manufacturing aligns with its broader push for operational efficiencies. By launching clinical evaluations for Horizon 2, CSL aims to strengthen its leadership in plasma-derived therapies and maintain a competitive edge in immunoglobulin supply.
Ongoing collaboration with the FDA and EMA signals a strong commitment to compliance and high global standards. Investors can expect further updates from CSL on the clinical trial's timeline and any potential impact on the final regulatory approval process.
What's next for CSL?
CSL anticipates starting Horizon 2 clinical work in mid-2027, using materials produced at Broadmeadows, in tandem with major construction at the Kankakee facility. The company is focusing on both scaling production capacity and streamlining technologies to meet ongoing global demand for immunoglobulin therapies.
Future updates from CSL are expected to clarify the clinical trial duration and any changes to regulatory timelines, providing shareholders with better visibility into the path to market for the new process.
CSL share price snapshot
Over the past 12 months, CSL shares have declined 56%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.
